Polysialylation is the enzymatic addition of a highly negatively charged sialic acid polymer to the non-reducing termini of glycans. Polysialylation plays an important role in development, and is involved in neurological diseases, neural tissue regeneration, and cancer. Polysialic acid (PSA) is also a biodegradable and non-immunogenic conjugate to therapeutic drugs to improve their pharmacokinetics. PSA chains vary in length, composition, and linkages, while the specific sites of polysialylation are important determinants of protein function. However, PSA is difficult to analyse by mass spectrometry (MS) due to its high negative charge and size. Most analytical approaches for analysis of PSA measure its degree of polymerization and monosaccharide composition, but do not address the key questions of site specificity and occupancy. Here, we developed a high-throughput LC-ESI-MS/MS glycoproteomics method to measure site-specific polysialylation of glycoproteins. This method measures site-specific PSA modification by using mild acid hydrolysis to eliminate PSA and sialic acids while leaving the glycan backbone intact, together with protease digestion followed by LC-ESI-MS/MS glycopeptide detection. PSAmodified glycopeptides are not detectable by LC-ESI-MS/MS, but become detectable after desialylation, allowing measurement of site-specific PSA occupancy. This method is an efficient analytical workflow for the study of glycoprotein polysialylation in biological and therapeutic settings.
Introduction
Protein glycosylation, the enzymatic addition of carbohydrates to a protein, is a common posttranslational modification that plays a variety of physiological roles. 1 Protein glycosylation is critical in protein folding and transport through the secretory pathway, and is also important for protein solubility and stability, cell-cell interactions, and ligand-receptor binding. [1] [2] [3] [4] N-linked glycosylation occurs at selected asparagine (N) residues within the consensus "sequon" N-X-S/T (where X ≠ proline). 5 N-linked glycans are pre-assembled on the membrane of the endoplasmic reticulum (ER) as a dolichol-linked Glc(3)Man(9)GlcNAc(2) structure (Glc, glucose; Man, mannose; and GlcNAc, N-Acetylglucosamine), and are transferred en bloc by the enzyme oligosaccharyltransferase to the polypeptide in the lumen of the ER. 3 Glycans are modified as proteins traverse the secretory pathway, leading to heterogeneity in the glycan structures in mature glycoproteins. 1, 6, 7 The presence and structures of glycans at particular sites have a major influence on protein conformation, stability, and function. 8 Mammalian glycans are commonly terminated by sialic acids, 9-carbon carboxylated monosaccharides. 9, 10 Although there are many sialic acid variants, N-acetylneuraminic acid (NeuAc) is the most common in human glycans. Glycans are typically monosialylated, but sialic acids can also be found as short oligosialyl chains (2-7 monosaccharides) and as polysialic acid (PSA) (≥ 8 monosaccharides), with an arbitrary length distinction between oligo-and polysialic acid. 9, 11 PSA is structurally heterogenous due to variability in the sialic acid type, modifications, glycosidic linkages, and degree of polymerization. 10 Only few polysialylated proteins have been identified, including neural cell adhesion molecule (NCAM), 12 synCAM-1, 13 neuropilin-2, 14 voltage-sensitive sodium channel, 15, 16 CCR7 chemokine, 17 E-selecting ligand-1, 18 CD36 in milk, 19 and the polysialyltransferases themselves. 20, 21 NCAM is the best-studied polysialylated protein, and carries α2-8-linked NeuAc PSA in two of its N-glycans. 11, [22] [23] [24] Bulky and negatively charged PSA-modified NCAM inhibits cell-cell interactions, thereby playing important roles in embryonic development, 11 neurological diseases, 11, 25, 26 tumour metastasis, 27 and neural tissue regeneration. 28 PSA also has important biotechnological applications. 11, 29 PSA is used as a protein conjugate (chemically/enzymatically attached to proteins) or as a delivery system (PSA micelles) to improve pharmacokinetics of therapeutic proteins. [29] [30] [31] [32] [33] [34] Thus, polysialylation is a post-translational modification with high physiological, pathological, and biotechnological relevance.
Analysis of PSA-modified glycoproteins is challenging due to the large size, high negative charge, and structural heterogeneity of PSA. Immuno-detection can detect protein polysialylation, 10, 35, 36 and detection with and without endosialidase treatment allows inference of the presence of PSAmodified proteins. [37] [38] [39] However, anti-PSA immunodetection provides no information about the sites of polysialylation, PSA structure and composition, the degree of polymerization, or the underlying glycan structures. Several approaches overcome some of these limitations. 40, 41 PSA degree of polymerization, sialic acid composition, and glycosidic linkages can be measured using: mild acid hydrolysis, derivatization, and HPLC; [42] [43] [44] [45] fluorometric C7/C9 analysis; 40, [45] [46] [47] high performance (high pH) anion-exchange chromatography pulsed electrochemical detection (HPAEC-PED); 48, 49 nuclear magnetic resonance (NMR); [50] [51] [52] [53] or mass spectrometry (MS) glycomics [54] [55] [56] [57] , including matrix-assisted laser desorption/ionization time-of-flight MS (MALDI-TOF MS), 56, 58, 59 gas chromatography-MS (GC-MS), 60 and electrospray ionization MS (ESI-MS). 57, 61 Therefore, a wide range of chemical and analytical tools are available to characterize released PSA chains. Three additional features of polysialylated glycoproteins are critical: sitespecific PSA localisation, PSA occupancy, and the underlying structure of the polysialylated glycan. Sites of PSA modification can be identified by site-directed mutagenesis of glycosylation sites with anti-PSA Western blotting, 22, 62 or immunoenrichment of tryptic PSA-glycopeptides, followed by deglycosylation and MS analysis. 13, 51, 63, 64 However, these methods do not measure site-specific PSA occupancy.
Here, we developed a high-throughput glycoproteomic workflow to measure site-specific polysialylation of glycoproteins ( Figure 1 ). This workflow combines mild acid hydrolysis to remove PSA from glycans, followed by LC-ESI-MS/MS for detection and site-specific relative quantification of previously polysialylated asialoglycopeptides ( Figure 1 ). By comparing glycoform abundance in the desialylated sample with that in the untreated control, site specific polysialylation can be inferred, its occupancy measured, and the underlying polysialylated glycan structure can be elucidated. 65, 66 After 6 days of incubation cells were harvested as described. 67 Expression of secreted polysialylated rHuNCAM was verified by SDS-PAGE and Coomassie Blue staining, and Western blot analysis using anti-His (A01620, Genscript) and anti-PSA-NCAM (MAB5324, Millipore) antibodies. rHuNCAM was purified from the culture supernatant of transiently transfected Expi293F cells using nickel sepharose resin and size-exclusion chromatography as previously described. 68, 69
Expression, purification, and activity of recombinant Endosialidase NF
The pCW(-lacZ) vector containing the MalE-thrombin-Endosialidase NF construct was a kind gift from Warren Wakarchuk. 37 Expression and purification of MalE-thrombin-Endosialidase NF (EndoNF) used a published method with minor modifications. 70 EndoNF retained in the amyloseagarose resin was eluted with working buffer supplemented with 10 mM maltose. The purity and quality of EndoNF were determined by SDS-PAGE and Coomassie Blue staining ( Supplementary   Figure 1 ).
To enzymatically de-polysialylate rHuNCAM, 5 µg of rHuNCAM was diluted in 50 mM sodium phosphate buffer pH 7.5, treated or not with 0.25 µg EndoNF (20:1 sample:EndoNF ratio), and incubated at 37 °C and 1500 rpm for 2 h in a MS100 thermoshaker incubator (LabGene Scientific).
Samples were precipitated with 4 volumes of 1:1 acetone:methanol, incubated at -20 °C for 16 h, and centrifuged at 20,000 rcf for 20 min at 4 °C. Pellets were reconstituted in 1X SDS-PAGE loading buffer, incubated at 65 °C for 15 min, and separated by SDS-PAGE using a 6% polyacrylamide gel. Separated proteins were either stained with Coomassie Blue or transferred onto nitrocellulose membrane (Bio-Rad) using an XCell II Blot Module (Invitrogen, Thermo Fisher Scientific). Western blots using anti-PSA antibody (mAb735, Abcam) were developed using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific), and images were captured using a GE Amersham Imager 600.
Mass Spectrometry sample preparation
Four treatments were tested: EndoNF alone, EndoNF followed by mild acid hydrolysis, mild acid hydrolysis only, and untreated control. For each treatment, 5 µg of purified rHuNCAM or serum purified human IgG (IgG) (I4506, Sigma-Aldrich) was prepared in triplicate. Samples were digested with 0.25 µg EndoNF (20:1 sample:EndoNF ratio) in 50 mM sodium phosphate buffer pH 7.5 at 37 °C and 1500 rpm for 2 h. Proteins were then denatured, reduced, alkylated, and precipitated as described. 71, 72 The precipitated protein pellets were resuspended in 20 µL of 50 mM ammonium bicarbonate and protease digested. rHuNCAM samples were sequentially digested with trypsin (30:1 sample:protease ratio), Asp-N (80:1 sample:protease ratio), and Glu-C (20:1 sample:protease ratio) by incubation in a thermoshaker at 37 °C and 1500 rpm for 16 h. Each protease was deactivated before the addition of the next enzyme by heating at 95 °C for 10 min for trypsin 73, 74 , and 5 min for Asp-N and Glu-C. IgG samples were digested with trypsin (30:1 sample:protease ratio) by incubation at 37 °C and 1500 rpm for 16 h. Trypsin activity was deactivated by heating at 95 °C for 10 min. Mild acid hydrolysis was performed by acidifying samples with 2% formic acid and heating at 95 °C for 1 h. All samples for MS analysis were desalted with C18 ZipTips (Millipore, USA), dried in a Genevac miVac centrifugal vacuum concentrator, and reconstituted in 0.1% formic acid at a concentration of 50 ng/µL.
Mass Spectrometry
Samples were analysed with an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) coupled to an UltiMate 3000 UHPLC system (Thermo Fisher Scientific). 
Results and Discussion

Generation of polysialylated recombinant HuNCAM
To develop a glycoproteomics workflow capable of measuring site-specific polysialylation, we required a polysialylated glycoprotein substrate. One of the best-studied polysialylated glycoproteins is NCAM, 11 N467 and N496 of rHuNCAM) (https://www.uniprot.org/uniprot/P13591). 11, [22] [23] [24] To obtain polysialylated human NCAM, we expressed a recombinant soluble human NCAM variant (rHuNCAM) in mammalian cells (Figure 2 and Supplementary Figure 2 ). Polysialylation of rHuNCAM was achieved by co-expression with human B4GALT1, human ST3GAL4, and human ST8SIA4. To verify that the purified rHuNCAM was polysialylated we performed Western blot analysis using anti-PSA and anti-NCAM antibodies with and without pretreatment with EndoNF endosialidase to remove PSA (Figure 3 ). EndoNF is a tail-spike protein from bacteriophage K1F that cleaves PSA leaving an oligosialic acid chain attached to the glycan. 37 rHuNCAM showed anti-PSA reactivity (Figure 3, lane 4) that was lost after EndoNF treatment (Figure 3, lane 5) , while there was anti-NCAM antibody reactivity in both samples (Figure 3, lanes 6 and 7) . We also observed a reduction in the apparent molecular weight of rHuNCAM after EndoNF treatment by Coomassie Blue stained SDS-PAGE (Figure 3, lanes 2 and 3) . Together, these results indicated that rHuNCAM was polysialylated. rHuNCAM was subsequently used as our polysialylated glycoprotein substrate for MS workflow development. 7) . PSA and NCAM were detected with anti-PSA (lanes 4-5) and anti-NCAM antibodies (lanes 6-7) respectively.
An LC-ESI-MS/MS method to measure site-specific polysialylation
Polysialylated glycopeptides are difficult to detect by standard LC-ESI-MS/MS glycoproteomic workflows due to the high molecular weight and negative charge of PSA glycans. 76 To enable sitespecific measurement of polysialylated glycopeptides by LC-ESI MS/MS, PSA must be removed ( Figure 1) . Indeed, using standard glycoproteomic workflows with only protease digestion and analysis of intact glycopeptides we could not detect PSA-modified glycopeptides from rHuNCAM ( Figure 4A and B, Supplementary Tables 2 and 3 ). We incorporated EndoNF digestion into a standard glycoproteomic workflow as EndoNF can digest PSA to oligosialic acid, 37, 77, 78 and we had observed that it efficiently removed anti-PSA antibody reactivity from rHuNCAM (Figure 3 ).
We then analysed the types and relative abundance of glycans detected at N467 or N496 in rHuNCAM, which correspond to the 5 th and 6 th N-linked sites of NCAM that are reported to be polysialylated on native NCAM. 11, [22] [23] [24] However, we observed no difference in the relative abundances of glycoforms at these sites in rHuNCAM samples with or without EndoNF digestion ( Figure 4A and B, Supplementary Table 2 and 3) . The predominant glycoform observed at N467 and N496 in both the untreated and EndoNF treated samples was the oligomannose HexNAc(2)Hex(5) glycan ( Figure 4A and B, Supplementary Table 2 and 3) . These results suggested that oligosialylated glycopeptides were not detectable by LC-ESI-MS/MS. The negatively charged oligosialic acid chain remaining after EndoNF treatment may reduce the ionisation efficiency of the glycopeptides in positive ion mode, resulting in diminished MS1 signals and limiting detection. To overcome this problem, we treated the samples with mild acid hydrolysis, to completely remove sialic acids. 16, 73, 74 As expected, after mild acid hydrolysis we could only detect asialylated glycoforms by MS ( Figure 4A and B, Supplementary Table 2 and 3 ).
This suggested that EndoNF treatment was not required, and indeed, desialylation with mild acid hydrolysis only resulted in equivalent detection of asialylated glycoforms ( Figure 4A and B, Supplementary Table 2 and 3 ). This treatment also allowed for the detection of several new glycoforms at both N467 and N496 ( Figure 4A and B, Supplementary Table 2 and 3 Table 3 ). The new glycoforms detected after hydrolysis (hybrid and complex Nglycans) were also the glycan scaffolds that have been previously reported to be polysialylated in bovine NCAM. 64 Therefore, complete removal of sialic acids by mild acid hydrolysis allowed the detection and relative quantification of polysialylated glycopeptides by LC-ESI-MS/MS. To allow focused analysis of glycopeptides containing N467 and N496, the sites known to be polysialylated in native NCAM, 11, [22] [23] [24] we optimized protease digestion and LC-ESI-MS/MS acquisition methods accordingly. However, this generated suboptimal conditions for detection of other N-glycopeptides from rHuNCAM. Therefore, to verify that our workflow did not perturb analysis of glycopeptides without PSA, we tested the workflow on serum-purified human immunoglobulin G (IgG), a non-polysialylated glycoprotein (Figure 6 , Supplementary Table 4 ).
This analysis focused on IgG2, for which glycopeptides were most robustly detected. IgG2 has one N-linked glycosylation site at N176 (https://www.uniprot.org/uniprot/P01859), which is predominantly occupied by bi-antennary glycans. 79 IgG2 glycoforms observed in the untreated sample included HexNAc(4)Hex(3)Fuc(1), HexNAc(4)Hex(4)Fuc(1), HexNAc(4)Hex(5)Fuc (1), HexNAc(4)Hex(4)Fuc(1)NeuAc(1), and HexNAc(4)Hex(5)Fuc(1)NeuAc(1) (Figure 6 , Supplementary Table 4 ). This glycoform distribution is similar to previous reports. 79 After EndoNF treatment, we did not detect any new glycoforms on IgG2, and there was no significant change in the relative abundance of the observed glycoforms compared to the untreated samples ( Figure 6 , Supplementary Table 4 ). This result was expected, given that IgG2 is not reported to contain PSA-modified glycans. Importantly, the only changes observed in IgG2 glycoform structure and abundance in samples treated with EndoNF and mild acid hydrolysis compared to untreated samples were the disappearance of previously monosialylated structures, and the increase in abundance of the corresponding unsialylated forms of these structures (Figure 6 , Supplementary Table 4 ). For example, we observed the disappearance of the HexNAc(4)Hex(4)Fuc(1)NeuAc(1) and HexNAc(4)Hex(5)Fuc(1)NeuAc(1) glycoforms in desialylated samples, and an increase in the abundance of the corresponding HexNAc(4)Hex(4)Fuc(1) and HexNAc(4)Hex(5)Fuc(1) structures (Figure 6 , Supplementary  Table 4 ). We did not detect any new glycoform in the desialylated sample. Since the relative abundance of nonsialylated glycoforms increases after desialylation, our workflow is more effective when comparing potentially polysialylated glycoproteins with their non-polysialylated counterparts. We also note that some defucosylation was observed with mild acid hydrolysis ( Figure 4 and Supplementary Tables 2 and 3 ), although the extent of fucose loss did not substantially impact determination of the site-specificity and occupancy of polysialylation.
Together, these results show that our workflow is a useful method to detect site-specific polysialylation in glycoproteins. Supplementary Table 4 .
Conclusions
PSA has key physiological roles and therapeutic applications. To facilitate the study of polysialylation and the development of new PSA technologies, we have developed an LC-ESI-MS/MS method that allows for the detection and measurement of site-specific polysialylation. Our method combines carefully selected proteases to generate peptides of appropriate length for LC-ESI-MS/MS detection with mild acid hydrolysis to eliminate sialic acids and newly developed Python scripts for data processing and calculation of glycoform abundance. We have demonstrated that this method distinguishes PSA-and non-PSA modified glycopeptides, can identify the precise peptides modified by PSA, and allows measurement of the site-specific extent of polysialylation. 
